GCA patients can rapidly reach remission at 3 months, taper off of steroids in 6 months, and stay in remission out to 1 year (primary endpoint: sustained remission* Week 12–52: 46% RINVOQ 15 mg + 26-wk CS taper [n=209] vs 29% placebo + 52-wk CS taper [n=112], P=0.002).²

Explore the Data

*Sustained remission was defined as the absence of GCA signs and symptoms from Week 12 through 52 and adherence to the protocol-defined CS-taper regimen.

CS=corticosteroid; GCA=giant cell arteritis.

INDICATION

RINVOQ is indicated for the treatment of adults with giant cell arteritis (GCA).

Limitations of Use: RINVOQ is not recommended for use in combination with other Janus kinase (JAK) inhibitors, biologic disease-modifying antirheumatic drugs (bDMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine.

Rapid and Substantial
Steroid Reduction^1,2

RINVOQ 15 mg + 26-wk CS taper (n=180) observed a reduction of patients’ median cumulative CS exposure by a substantial numerical difference of 40% relative to those on placebo + 52-wk CS taper (n=90) (1615 mg vs 2882 mg through Week 52)

See Steroid Reduction Data Through Week 52

Durable Remission¹

Significantly higher remission at Week 12 and maintained out to 1 year

See Complete Remission Data Up to Week 52

Well-Studied Safety^1,3,4

Safety data from 27 clinical trials across 9 approved indications in rheumatology, dermatology, and gastroenterology, including in an older patient population (mean age 71) with GCA

See Safety Profile

^†Complete remission was defined as achieving absence of GCA signs and symptoms, adherence to the protocol-defined CS-taper regimen, normalization of ESR (to ≤30 mm/hr), and normalization of hsCRP (to <1 mg/dL).

Committed to working toward >95% preferred Medicare Part D and National Commercial Formulary Coverage in GCA

For GCA, RINVOQ is indicated as a FIRST-LINE THERAPY

How much do your patients pay?

MEDICARE PART D

Low Income Subsidy

of RINVOQ rheumatology Medicare patients^‡ filled their prescription through the Medicare Part D Extra Help program, also known as the low-income subsidy (LIS)⁶

Medicare Part D Redesign

In <variable month> <variable year>, standard Medicare patients could pay as low as <$XX>/month for all of their pharmacy drugs, including RINVOQ⁶

In <variable year>, patients with Medicare Part D Extra Help pay no more than <$XX> per prescription.⁶

^‡<XX>% of RINVOQ patients are estimated to be enrolled in LIS. Based on Medicare Part D rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis claims data from <variable month> <variable year> through <variable month> <variable year>.⁶

COMMERCIAL

of Commercial claims for a filled RINVOQ prescription cost patients $0–$5^7,§

Your eligible, commercially insured patients may pay as little as $0 per treatment with the RINVOQ Complete Savings Card.^¶

^§Based upon paid Commercial claims data from national data providers for a filled RINVOQ prescription for RA, PsA, AS and nr-axSpA for the period <variable month/variable year>-<variable month/variable year>, inclusive of savings card redemptions.⁷

^¶RINVOQ Complete Savings Card Terms and Conditions Eligibility: Available to patients with commercial insurance coverage for RINVOQ who meet eligibility criteria.  This co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit RINVOQSavingsCard.com or call 1.800.2RINVOQ for additional information. To learn about AbbVie's privacy practices and your privacy choices, visit https://abbv.ie/corprivacy.

Patient's actual out-of-pocket cost may vary depending on their insurance coverage and eligibility for support programs.

See Access Information for Additional Indications

Learn About Patient Support

Please see Important Safety Information, including BOXED WARNING on Serious Infections, Mortality, Malignancies, Major Adverse Cardiovascular Events, and Thrombosis, below.

Learn more about these and the full Important Safety Information below

RINVOQ (upadacitinib) Met Its Primary Endpoint of Sustained Remission from Week 12 through Week 52

Significantly higher rates of sustained remission achieved in patients on RINVOQ 15 mg + 26-wk CS taper vs placebo + 52-wk CS taper^1,2

SELECT-GCA

Sustained remission from Week 12 through 52 (primary endpoint)

Primary Endpoint: Sustained Remission from Weeks 12–52.

Sustained remission: Absence of GCA signs and symptoms from Week 12 through 52 and adherence to the protocol-defined CS-taper regimen.

	Blinded 52-wk CS* Taper (mg)
Baseline	20	30	40	50	60
Week 1	17	25	35	40	50
Week 2	17	20	30	35	40
Week 3	15	17	25	30	35
Week 4	15	17	20	25	30
Week 5	12	15	17	20	25
Week 6	10	15	17	17	20
Week 7	10	12	15	17	17
Week 8	10	10	15	16	17
Week 9	10	10	12	15	15
Week 10	9	10	10	12	15
Week 11	9	10	10	10	12
Week 12	9	9	10	10	10
Week 13	9	9	10	10	10
Week 14	8	9	9	10	10
Week 15+	Taper 1 mg every 4 weeks until 0 mg at Week 46	Taper 1 mg every 4 weeks until 0 mg at Week 48	Taper 1 mg every 4 weeks until 0 mg at Week 50	Taper 1 mg every 4 weeks until 0 mg at Week 51	Taper 1 mg every 4 weeks until 0 mg at Week 52

	Blinded 26-wk CS* Taper (mg)
Baseline	20	30	40	50	60
Week 1	15	25	35	40	50
Week 2	12	20	30	35	40
Week 3	12	15	25	30	35
Week 4	10	12	20	25	30
Week 5	9	12	15	20	25
Week 6	8	10	12	15	20
Week 7	7	9	12	12	15
Week 8	6	8	10	12	12
Week 9	6	7	9	10	12
Week 10	5	6	8	9	10
Week 11	5	6	7	8	9
Week 12	4	5	6	7	8
Week 13	4	5	5	6	7
Week 14	3	4	5	5	6
Week 15+	Taper 1 mg every 2 weeks until 0 mg at Week 20	Taper 1 mg every 2 weeks until 0 mg at Week 22	Taper 1 mg every 4 weeks until 0 mg at Week 24	Taper 1 mg every 2 weeks until 0 mg at Week 25	Taper 1 mg every 2 weeks until 0 mg at Week 26

MEAN (SD) or n (%)	Placebo + 52-wk CS Taper (n=112, PYs=94.3)	RINVOQ 15 mg + 26-wk CS Taper (n=209, PYs=178.1)
Female, n (%)	77 (68.8)	156 (74.6)
Age (years), mean (SD)	71.6 (7.3)	70.8 (7.3)
Age group (years), n (%)
<65	17 (15.2)	42 (20.1)
≥65 to <75	59 (52.7)	102 (48.8)
≥75	36 (32.1)	65 (31.1)
BMI (kg/m²), mean (SD)	25.8 (4.3)	25.3 (4.6)
Prior use of IL-6 inhibitor, n (%)	7 (6.2)	9 (4.3)
Baseline CS dose (mg), mean (SD)	34.6 (11.9)	34.6 (12.7)
New onset of GCA, n (%)	76 (67.9)	148 (70.8)
Relapsing GCA, n (%)	36 (32.1)	61 (29.2)
Disease duration since diagnosis (days), mean (SD)
New-onset disease	38.2 (14.8)	39.5 (28.1)
Relapsing disease	665.7 (816.3)	664.9 (687.5)
ESR (mm/hr), mean (SD)	21.7 (25.5)	19.5 (17.5)
hsCRP (mg/dL), median (min, max)	0.23 (0.02, 5.83)	0.24 (0.02, 10.10)

GCA patients can rapidly reach remission at 3 months, taper off of steroids in 6 months, and stay in remission out to 1 year (primary endpoint: sustained remission* Week 12–52: 46% RINVOQ 15 mg + 26-wk CS taper [n=209] vs 29% placebo + 52-wk CS taper [n=112], P=0.002).2

Rapid and Substantial Steroid Reduction1,2

Durable Remission1

Well-Studied Safety1,3,4

Committed to working toward >95% preferred Medicare Part D and National Commercial Formulary Coverage in GCA

For GCA, RINVOQ is indicated as a FIRST-LINE THERAPY

RINVOQ (upadacitinib) Met Its Primary Endpoint of Sustained Remission from Week 12 through Week 52

Significantly higher rates of sustained remission achieved in patients on RINVOQ 15 mg + 26-wk CS taper vs placebo + 52-wk CS taper1,2

SELECT-GCA

IMPORTANT SAFETY INFORMATION & INDICATIONS1

INDICATION1

IMPORTANT SAFETY INFORMATION FOR RINVOQ/RINVOQ LQ (upadacitinib)

SERIOUS INFECTIONS

MORTALITY

MALIGNANCIES

MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE)

THROMBOSIS

HYPERSENSITIVITY

GASTROINTESTINAL PERFORATIONS

LABORATORY ABNORMALITIES

EMBRYO-FETAL TOXICITY

VACCINATION

MEDICATION RESIDUE IN STOOL

LACTATION

HEPATIC IMPAIRMENT

ADVERSE REACTIONS